AbbVie Inc. (NYSE:ABBV) Stock Holdings Increased by Brown Financial Advisory

Brown Financial Advisory raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 8.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,920 shares of the company’s stock after acquiring an additional 155 shares during the period. AbbVie makes up 0.2% of Brown Financial Advisory’s holdings, making the stock its 23rd largest position. Brown Financial Advisory’s holdings in AbbVie were worth $341,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Groupama Asset Managment raised its stake in shares of AbbVie by 40.3% in the 3rd quarter. Groupama Asset Managment now owns 135,749 shares of the company’s stock worth $27,000 after buying an additional 38,974 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new position in shares of AbbVie in the 3rd quarter worth $28,000. Fiduciary Advisors Inc. acquired a new position in shares of AbbVie in the 4th quarter worth $29,000. Retirement Wealth Solutions LLC acquired a new position in shares of AbbVie in the 4th quarter worth $35,000. Finally, Marquette Asset Management LLC acquired a new position in shares of AbbVie in the 3rd quarter worth $39,000. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.25% of the stock is owned by insiders.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $183.90 on Friday. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $207.32. The business has a 50-day moving average of $176.43 and a two-hundred day moving average of $184.84. The stock has a market capitalization of $324.98 billion, a P/E ratio of 63.85, a P/E/G ratio of 1.77 and a beta of 0.58. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 244.01% and a net margin of 9.22%. During the same period last year, the firm posted $2.79 EPS. On average, equities research analysts predict that AbbVie Inc. will post 10.09 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ABBV shares. Citigroup decreased their target price on AbbVie from $215.00 to $205.00 and set a “buy” rating on the stock in a report on Tuesday. Leerink Partnrs upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Friday, November 22nd. Bank of America restated a “neutral” rating and issued a $191.00 target price on shares of AbbVie in a report on Tuesday, December 10th. Guggenheim lifted their price target on AbbVie from $212.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Wolfe Research started coverage on AbbVie in a report on Friday, November 15th. They set an “outperform” rating and a $205.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $205.00.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.